

Cs Chim

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8343372/cs-chim-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

2,253
citations

24
h-index

45
g-index

93
ext. papers

2,518
ext. citations

6
avg, IF

4.68
L-index

#	Paper	IF	Citations
85	The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain.. <i>Therapeutic Advances in Hematology</i> , 2022 , 13, 20406207221082043	5.7	0
84	Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone. <i>Blood</i> , 2021 , 138, 1648-1648	2.2	0
83	Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone. <i>Blood</i> , 2021 , 138, 1661-1661	2.2	0
82	A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma. <i>Scientific Reports</i> , 2021 , 11, 7009	4.9	1
81	miR-1250-5p is a novel tumor suppressive intronic miRNA hypermethylated in non-Hodgkin's lymphoma: novel targets with impact on ERK signaling and cell migration. <i>Cell Communication and Signaling</i> , 2021 , 19, 62	7.5	2
80	3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma. <i>Hematology</i> , 2021 , 26, 652-655	2.2	0
79	Case series: MRD negativity assessment using C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2021 , 12, 20406207211030369	5.7	0
78	Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 679-684	5.1	6
77	Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma. <i>Journal of Pharmacy and Pharmacology</i> , 2020 , 72, 728-737	4.8	7
76	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020 , 95, 503-509	7.1	6
75	Frequent methylation of the tumour suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification. <i>British Journal of Haematology</i> , 2020 , 190, 249-261	4.5	6
74	Epigenetic silencing of miR-342-3p in B cell lymphoma and its impact on autophagy. <i>Clinical Epigenetics</i> , 2020 , 12, 150	7.7	4
73	Primary refractory multiple myeloma: a real-world experience with 85 cases. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2868-2875	1.9	3
72	Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: Experience in a resource-constrained setting. <i>Hematological Oncology</i> , 2020 , 38, 726-736	1.3	9
71	Epigenetic silencing of long non-coding RNA in multiple myeloma: impact on prognosis and myeloma dissemination. <i>Cancer Cell International</i> , 2020 , 20, 403	6.4	7
70	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1885-1893	1.9	2
69	Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR. <i>Frontiers in Oncology</i> , 2020 , 10, 611021	5.3	0

68	Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2019 , 9, 449	5.3	11
67	Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact. <i>Clinical Epigenetics</i> , 2019 , 11, 71	7.7	16
66	Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. <i>Leukemia and Lymphoma</i> , 2019 , 60, 471-476	1.9	6
65	Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma. <i>Hematology</i> , 2019 , 24, 533-537	2.2	
64	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2305-2317	1.9	9
63	Molecular detection of minimal residual disease in multiple myeloma. <i>British Journal of Haematology</i> , 2018 , 181, 11-26	4.5	25
62	Epigenetic silencing of EVL/miR-342 in multiple myeloma. <i>Translational Research</i> , 2018 , 192, 46-53	11	12
61	Epigenetic silencing of LPP/miR-28 in multiple myeloma. <i>Journal of Clinical Pathology</i> , 2018 , 71, 253-258	3.9	11
60	Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses. <i>Clinical Epigenetics</i> , 2018 , 10, 158	7.7	1
59	Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma. <i>Scientific Reports</i> , 2018 , 8, 13522	4.9	10
58	Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia. <i>Annals of Hematology</i> , 2017 , 96, 871-872	3	24
57	High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 107	22.4	18
56	Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016 , 7, 82400-82410	3.3	19
55	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016 , 91, 575-80	7.1	60
54	LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens. <i>European Journal of Haematology</i> , 2015 , 94, 330-5	3.8	16
53	DNA methylation of tumor suppressor protein-coding and non-coding genes in multiple myeloma. <i>Epigenomics</i> , 2015 , 7, 985-1001	4.4	23
52	Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 103	22.4	33
51	Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma. <i>Molecular Cancer</i> , 2015 , 14, 175	42.1	37

50	Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways. <i>Oncotarget</i> , 2015 , 6, 44422-36	3.3	16
49	Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. <i>Journal of Translational Medicine</i> , 2014 , 12, 52	8.5	31
48	RANKL expression in myeloma cells is regulated by a network involving RANKL promoter methylation, DNMT1, microRNA and TNF α in the microenvironment. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014 , 1843, 1834-8	4.9	16
47	Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival. <i>Hematological Oncology</i> , 2014 , 32, 205-11	1.3	2
46	Methylation of miR-155-3p in mantle cell lymphoma and other non-Hodgkin's lymphomas. <i>Oncotarget</i> , 2014 , 5, 9770-82	3.3	23
45	Epigenetic inactivation of the MIR129-2 in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2013 , 6, 16	22.4	50
44	Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide. <i>Annals of Hematology</i> , 2013 , 92, 855-7	3	4
43	Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NF κ B pathway. <i>Molecular Cancer</i> , 2013 , 12, 173	42.1	60
42	Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL. <i>Cancer Cell International</i> , 2013 , 13, 122	6.4	11
41	Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD. <i>Journal of Hematology and Oncology</i> , 2012 , 5, 28	22.4	11
40	Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies. <i>Expert Review of Molecular Diagnostics</i> , 2012 , 12, 755-65	3.8	14
39	DNA Methylation of Tumor Suppressive miRNAs in Non-Hodgkin's Lymphomas. <i>Frontiers in Genetics</i> , 2012 , 3, 233	4.5	11
38	Epigenetic inactivation of the miR-124-1 in haematological malignancies. <i>PLoS ONE</i> , 2011 , 6, e19027	3.7	99
37	Epigenetic inactivation of the MIR34B/C in multiple myeloma. <i>Blood</i> , 2011 , 118, 5901-4	2.2	57
36	Epigenetic silencing of MIR203 in multiple myeloma. <i>British Journal of Haematology</i> , 2011 , 154, 569-78	4.5	59
35	Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. <i>Journal of Cellular and Molecular Medicine</i> , 2011 , 15, 2760-7	5.6	79
34	Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms. <i>Journal of Translational Medicine</i> , 2011 , 9, 197	8.5	36
33	Epigenetic inactivation of the miR-34a in hematological malignancies. <i>Carcinogenesis</i> , 2010 , 31, 745-50	4.6	144

32	Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients. <i>Journal of Translational Medicine</i> , 2010 , 8, 124	8.5	6
31	Restoration of chemosensitivity by bortezomib: implications for refractory myeloma. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 237-40	19.4	8
30	Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach. <i>Clinical Lymphoma and Myeloma</i> , 2008 , 8, 331-9		27
29	Pulmonary interstitial amyloidosis complicating multiple myeloma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 504-6	2.2	8
28	Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. <i>Journal of Clinical Pathology</i> , 2007 , 60, 664-9	3.9	29
27	Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. <i>Journal of Clinical Pathology</i> , 2007 , 60, 104-6	3.9	32
26	Pathological bone fracture in non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3175-6	2.2	1
25	Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma. <i>Human Pathology</i> , 2007 , 38, 1849-57	3.7	26
24	Adverse prognostic impact of CDKN2B hyper-methylation in acute promyelocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 815-25	1.9	11
23	Infrequent Wnt inhibitory factor-1 (Wif-1) methylation in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2006 , 30, 1135-9	2.7	24
22	Extrapulmonary tuberculous abscess in chronic lymphocytic leukaemia (CLL) treated with fludarabine: case report and review of literature. <i>American Journal of Hematology</i> , 2005 , 79, 246-7	7.1	5
21	Side effects and good effects from new chemotherapeutic agents. Case 3. Bortezomib in primary refractory plasmacytoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2426-8	2.2	15
20	Eosinophilic leukemic transformation in polycythemia rubra vera (PRV). <i>Leukemia and Lymphoma</i> , 2005 , 46, 447-50	1.9	3
19	Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. <i>Archives of Internal Medicine</i> , 2005 , 165, 2651-8		81
18	Plasma cell problems: Case 2. Extramedullary cardiac plasmacytoma presenting with cardiac tamponade. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3140-3	2.2	6
17	Primary follicular lymphoma of the small intestine. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1463-6	1.9	8
16	Mucosa-associated lymphoid tissue (MALT) lymphoma of the jejunum: an elusive cause of recurrent upper gastrointestinal bleeding. <i>Leukemia and Lymphoma</i> , 2004 , 45, 405-7	1.9	2
15	Primary granulocytic sarcoma of the mediastinum. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1931-3	1.9	13

14	Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. <i>Blood</i> , 2004 , 103, 216-21	2.2	306
13	SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. <i>Blood</i> , 2004 , 103, 4630-5	2.2	197
12	Common malignancies with uncommon sites of presentation: case 2. Mantle-cell lymphoma of the prostate. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4456-8	2.2	10
11	Unusual abdominal tumors: case 3. Multiple lymphomatous polyposis in lymphoma of colon. <i>Journal of Clinical Oncology</i> , 2003 , 21, 953-5	2.2	13
10	Primary CD56 positive lymphomas of the gastrointestinal tract. <i>Cancer</i> , 2001 , 91, 525-33	6.4	50
9	Methylation of p15 and p16 genes in adult acute leukemia. <i>Cancer</i> , 2001 , 91, 2222-2229	6.4	58
8	Splenic rupture as the presenting symptom of blastic crisis in a patient with Philadelphia-negative, bcr-abl-positive ET. <i>American Journal of Hematology</i> , 2001 , 66, 70-1	7.1	1
7	Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2033-40	2.2	97
6	Giant pronormoblasts in parvovirus-associated pure red cell aplasia. <i>American Journal of Hematology</i> , 2000 , 65, 289	7.1	3
5	Two unusual lymphomas. Case 2: pulmonary intravascular lymphomatosis. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3733-5	2.2	13
4	Meningeal relapse in Hodgkin's disease. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1153-5	2.2	19
3	Advanced stage and unfavorable Hodgkin's disease in the Chinese-a 20-year experience. <i>American Journal of Hematology</i> , 1999 , 61, 159-63	7.1	1
2	Bone marrow necrosis in bone marrow transplantation: the role of MR imaging. <i>Bone Marrow Transplantation</i> , 1998 , 22, 1125-8	4.4	5
1	Autologous bone marrow transplantation for primary nasal T/NK cell lymphoma. <i>Bone Marrow Transplantation</i> , 1997 , 19, 91-3	4.4	60